Altimmune's RSI-81 bounce looks like an overbought bear-market rally within a confirmed downtrend, compounded by extreme cash burn and justified 22% short interest, and the rejected, implausible analyst price target means headline upside figures should not be trusted here, even though the company has beaten earnings in 3 of its last 4 quarters.
Thesis pillars
- Overbought Bear Rally Momentum→Stable
- Extreme Cash Burn→Stable
- Justified Elevated Short Interest→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 6, 2026
Altimmune, Inc. (ALT) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $2.10: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 22%; Below-average business quality; Negative price momentum.
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and alcohol-associated liver disease. The company has no... Read more
Sell if holding. Engine safety override at $2.10: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 22%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 23, MACD bearish. Score 4.7/10, moderate confidence.
Passes 4/8 gates (clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: speculative.
About Altimmune, Inc.
About Altimmune, Inc.
Altimmune's pivotal Phase 2b IMPACT trial of pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist, showed 58.2% and 52.1% of MASH patients achieving fibrosis-neutral disease resolution at 24 weeks on the 1.2 mg and 1.8 mg doses versus 19.9% on placebo, with continued antifibrotic improvement through 48 weeks. The clinical-stage company has generated no product revenue, reported an $88.1 million net loss for 2025 against a $649.5 million accumulated deficit, and holds FDA Breakthrough Therapy and Fast Track designations for pemvidutide in MASH.
Altimmune's near-term funding has historically come from government grants and contracts rather than product sales, and its entire clinical pipeline centers on pemvidutide across three indications — MASH, alcohol use disorder, and alcohol-associated liver disease — after the company acquired the molecule through its 2019 purchase of Spitfire Pharma. Following a December 2025 End-of-Phase 2 meeting, the FDA agreed to Altimmune's use of AIM-MASH AI Assist, the agency's first FDA-qualified AI pathology tool, in the planned 52-week, biopsy-driven Phase 3 MASH trial the company intends to initiate in 2026, while European regulators are separately being consulted to finalize that protocol. Pemvidutide is protected by a patent portfolio covering composition, formulation, and methods of use with expiration dates extending into the 2040s including expected patent-term extension.
Show full overview
Every Altimmune value driver traces back to one molecule: pemvidutide is simultaneously the company's MASH, alcohol use disorder, and alcohol-associated liver disease program, so a Phase 3 safety or efficacy miss in any one indication could cloud investor and regulatory confidence in the others even though the trials are clinically distinct. That concentration is amplified by trial design risk specific to the upcoming MASH study: the FDA's December 2025 guidance calls for biopsy-driven endpoints in the registrational trial, a more invasive and slower readout than the non-invasive tests (ELF, LSM) that carried the Phase 2b data, meaning the Phase 3 program's timeline and eventual approvability depend on a data package Altimmune has not yet generated.
See also: Healthcare · Biotechnology
From Altimmune, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Altimmune, Inc.
Latest news
- NEWS Altimmune Appoints Peter Greenleaf and Alex Howarth to Board of Directors — fiscal.ai Oct 27, 2026 positive
- NEWS Altimmune to Present New Pemvidutide Data at AASLD The Liver Meeting 2026 — fiscal.ai Oct 19, 2026 neutral
- NEWS Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17 — benzinga Sep 23, 2026 positive
- NEWS 9 Health Care Stocks Whale Activity In Today’s Session — benzinga Aug 14, 2026 neutral
- NEWS Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate — benzinga Aug 12, 2026 positive
Generated 2026-10-29T11:08:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $2.10: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 22%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 23, MACD bearish. Prior stop was $1.95. Score 4.7/10, moderate confidence.
Resistance target: $2.79 (+32.9% upside). Prior stop was $1.95. Stop-loss: $1.95.
DATA_ISSUE: analyst_target_implausible (raw $17.11 vs price $2.10 — ratio 8.1×). Rejected, falling back to technical TP.; Quality below floor (1.8 < 4.0).
Altimmune, Inc. trades at a P/E of N/A (forward -3.1). TrendMatrix value score: 5.0/10. Verdict: Sell.
15 analysts cover ALT with a consensus score of 4.1/5. Average price target: $17.
What does Altimmune, Inc. do?Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a balanced 1:1 glucagon/GLP-1 dual...
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and alcohol-associated liver disease. The company has no product revenue, reported an $88.1 million net loss for 2025 and a $649.5 million accumulated deficit, and holds FDA Breakthrough Therapy and Fast Track designations for pemvidutide ahead of a planned 2026 Phase 3 MASH trial.